Current Assets
Short- term Investments
Vertex Pharmaceuticals Short- term Investments increased by 15.1% to $1.75B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 14.9%, from $1.53B to $1.75B. Over 5 years (FY 2020 to FY 2025), Short- term Investments shows an upward trend with a 17.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
Metric ID:
current_assets_marketable_securities_currentHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $644.32M | $685.19M | $729.90M | $638.00M | $551.20M | $599.20M | $274.50M | $1.12B | $1.09B | $818.00M | $849.20M | $1.01B | $1.22B | $1.29B | $1.55B | $1.53B | $1.41B | $1.35B | $1.52B | $1.75B |
| QoQ Change | — | +6.3% | +6.5% | -12.6% | -13.6% | +8.7% | -54.2% | +309.5% | -3.5% | -24.6% | +3.8% | +19.3% | +19.9% | +5.8% | +20.3% | -1.3% | -7.6% | -4.5% | +13.1% | +15.1% |
| YoY Change | — | — | — | — | -14.5% | -12.5% | -62.4% | +76.2% | +96.9% | +36.5% | +209.4% | -9.9% | +12.0% | +57.1% | +82.1% | +50.6% | +16.1% | +4.8% | -1.5% | +14.9% |
Range$274.50M – $1.75B
CAGR+23.5%
Avg YoY Growth+34.7%
Median YoY Growth+15.5%
Current Streak2 quarters growth
Short- term Investments at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's short- term investments?
- Vertex Pharmaceuticals (VRTX) reported short- term investments of $1.75B in Q1 2026.
- How has Vertex Pharmaceuticals's short- term investments changed year-over-year?
- Vertex Pharmaceuticals's short- term investments increased by 14.9% year-over-year, from $1.53B to $1.75B.
- What is the long-term trend for Vertex Pharmaceuticals's short- term investments?
- Over 5 years (2020 to 2025), Vertex Pharmaceuticals's short- term investments has grown at a 17.8% compound annual growth rate (CAGR), from $670.70M to $1.52B.